The standard treatment for patients with FLT3-mutated AML is chemotherapy combined with an FLT3 inhibitor.31 In AML post allo-HSCT, the prophylactic use of sorafenib has shown to improve survival.32,33 Furthermore, the prevalence and implications of FLT3 mutation in CMML are currently a matter of discussion. This evidence concerns the gene FLT3 and acute myeloid leukemia.